The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors

摘要: Abstract Objectives In daily practice, some patients with certain clinical characteristics may have better responses to the administration of epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors (TKIs). It is therefore reasonable stratify and weigh importance these parameters which not only affect patients' TKIs but also progression-free survival (PFS) other than impact EGFR mutation status per se. Materials methods This retrospective study evaluated -mutant, non-small cell lung cancer who received EGFR-TKIs as a first-line therapy between January 2011 December 2013. Several potential prognostic factors were analyzed respect PFS, results this analysis validated in another time cohort. Results A total 262 included study. Age≤40 years, uncommon mutations, poor performance status, more sites distal metastasis, blood lymphocyte monocyte ratio≤3 independently associated PFS. These five scoring system three groups A, B, C, formed based on scores 0–1, 2, ≥3, respectively. test group, PFS was 15.7 month, 9.3 4.0 month respectively ( p Conclusions The appears valid reproducible for prognosis -mutant EGFR-TKIs.